Full Press Release Details
ADVISORY, Feb. 22, 2016 (GLOBE NEWSWIRE) --
Axsome Therapeutics, Inc. (Nasdaq:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will visit the Nasdaq MarketSite in Times Square to celebrate its initial public offering (IPO) on November 19, 2015.
In honor of the occasion, Herriot Tabuteau, M.D., Chief Executive Officer, and other members of the Axsome team will ring the Opening Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Tuesday, February 23, 2016 – 9:15 a.m. to 9:30 a.m. ET
Axsome Therapeutics Media Contact:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For photos from ceremonies and events visit our Instagram Page:
For news tweets, please visit our Twitter page at:
For exciting viral content and ceremony photos visit our Tumblr Page:
A LiveStream of the Nasdaq Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders. Axsome’s product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05. AXS-02 is currently in a Phase 3 trial in complex regional pain syndrome (CRPS), with additional Phase 3 trials planned in knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP) associated with Modic changes (MCs). A Phase 3 trial in treatment resistant depression (TRD) is currently planned with AXS-05. AXS-02 and AXS-05 are investigational and are not yet approved. No claims on the safety or efficacy of these product candidates are supported by the FDA..
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.